Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
Identifieur interne : 00B758 ( Main/Exploration ); précédent : 00B757; suivant : 00B759Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
Auteurs : Cornelis J. A. Punt [Pays-Bas] ; Attila Nagy [Hongrie] ; Jean-Yves Douillard [France] ; Arie Figer [Israël] ; Torben Skovsgaard [Danemark] ; John Monson [Royaume-Uni] ; Carlo Barone [Italie] ; George Fountzilas [Grèce] ; Hanno Riess [Allemagne] ; Eugene Moylan [Australie] ; Delyth Jones [Royaume-Uni] ; Juergen Dethling [Royaume-Uni] ; Jessica Colman [Royaume-Uni] ; Lorna Coward [Royaume-Uni] ; Stuart Macgregor [Royaume-Uni]Source :
- Lancet : (British edition) [ 0140-6736 ] ; 2002.
Descripteurs français
- Pascal (Inist)
- Tumeur maligne, Côlon, Classification par stade, Indice gravité, Traitement, Chimiothérapie, Fluorouracil, Traitement associé, Edrécolomab, Etude comparative, Efficacité traitement, Randomisation, Modalité traitement, Anticancéreux, Homme, Fluoropyrimidine dérivé, Pyrimidine dérivé, Acide folinique.
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background: Edrecolomab is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary data suggested that it might be of use in the adjuvant treatment of patients with resected stage III colon cancer. We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients. Methods: After surgery, 2761 patients were randomly assigned edrecolomab plus fluorouracil-folinic acid (combination therapy [n=912]); fluorouracil-folinic acid alone (chemotherapy [n=927]); or edrecolomab alone (edrecolomab monotherapy [n=922]). Patients were assessed for survival and disease recurrence after surgery. The primary endpoint tested the hypothesis that combination therapy improved overall survival relative to chemotherapy. The key secondary endpoint was to test whether edrecolomab monotherapy was non-inferior to chemotherapy in terms of disease-free survival. Analysis was by intention to treat. Findings: Median follow-up time was 26 months (IQR 20-36). 3-year overall survival on combination therapy was no different from that on chemotherapy (74.7% vs 76.1%, hazard ratio 0-94 [95% Cl 0.76-1.15], p=0.53). Disease-free survival was significantly lower on edrecolomab monotherapy than on chemotherapy (53.0% vs 65-5%, 0.62 [0.53-0.73], p<0.0001). Hypersensitivity reactions occurred in 452 (25%) patients receiving edrecolomab, causing treatment discontinuation in 71 (4%). The addition of edrecolomab to chemotherapy did not increase neutropenia, diarrhoea, or mucositis. Interpretation: The addition of edrecolomab to fluorouracil and folinic acid in the adjuvant treatment of resected stage III colon cancer does not improve overall or disease-free survival, and edrecolomab monotherapy is associated with significantly shorter overall and disease-free survival than fluorouracil and folinic acid and is therefore an inferior treatment option. Edrecolomab is well tolerated and its addition to fluorouracil and folinic acid does not increase the toxicity of chemotherapy.
Affiliations:
- Allemagne, Australie, Danemark, France, Grèce, Hongrie, Israël, Italie, Pays-Bas, Royaume-Uni
- Berlin, Latium, Pays de la Loire
- Berlin, Nantes, Rome
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 005615
- to stream PascalFrancis, to step Curation: 000B24
- to stream PascalFrancis, to step Checkpoint: 005462
- to stream Main, to step Merge: 00C583
- to stream Main, to step Curation: 00B758
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study</title><author><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J. A." last="Punt">Cornelis J. A. Punt</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medical Oncology, University Medical Center St Radboud, PO Box 9101</s1><s2>6500 HB Nijmegen</s2><s3>NLD</s3><sZ>1 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>6500 HB Nijmegen</wicri:noRegion></affiliation></author><author><name sortKey="Nagy, Attila" sort="Nagy, Attila" uniqKey="Nagy A" first="Attila" last="Nagy">Attila Nagy</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Csoinoky Hospital</s1><s2>Veszprém</s2><s3>HUN</s3><sZ>2 aut.</sZ></inist:fA14><country>Hongrie</country><wicri:noRegion>Csoinoky Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Douillard, Jean Yves" sort="Douillard, Jean Yves" uniqKey="Douillard J" first="Jean-Yves" last="Douillard">Jean-Yves Douillard</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre Rene Gauducheau</s1><s2>Nantes</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Figer, Arie" sort="Figer, Arie" uniqKey="Figer A" first="Arie" last="Figer">Arie Figer</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Ichilov Hospital</s1><s2>Tel Aviv</s2><s3>ISR</s3><sZ>4 aut.</sZ></inist:fA14><country>Israël</country><wicri:noRegion>Ichilov Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Skovsgaard, Torben" sort="Skovsgaard, Torben" uniqKey="Skovsgaard T" first="Torben" last="Skovsgaard">Torben Skovsgaard</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Heriev Hospital</s1><s2>Heriev</s2><s3>DNK</s3><sZ>5 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Heriev Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Monson, John" sort="Monson, John" uniqKey="Monson J" first="John" last="Monson">John Monson</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Hull</s1><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>University of Hull</wicri:noRegion></affiliation></author><author><name sortKey="Barone, Carlo" sort="Barone, Carlo" uniqKey="Barone C" first="Carlo" last="Barone">Carlo Barone</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Università Cattolica</s1><s2>Rome</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Fountzilas, George" sort="Fountzilas, George" uniqKey="Fountzilas G" first="George" last="Fountzilas">George Fountzilas</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Aristotle University of Thessalonlkl</s1><s3>GRC</s3><sZ>8 aut.</sZ></inist:fA14><country>Grèce</country><wicri:noRegion>Aristotle University of Thessalonlkl</wicri:noRegion></affiliation></author><author><name sortKey="Riess, Hanno" sort="Riess, Hanno" uniqKey="Riess H" first="Hanno" last="Riess">Hanno Riess</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Virchow Hospital</s1><s2>Berlin</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Moylan, Eugene" sort="Moylan, Eugene" uniqKey="Moylan E" first="Eugene" last="Moylan">Eugene Moylan</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Liverpool Hospital</s1><s2>New South Wales, Australia</s2><s3>AUS</s3><sZ>10 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Liverpool Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Jones, Delyth" sort="Jones, Delyth" uniqKey="Jones D" first="Delyth" last="Jones">Delyth Jones</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Dethling, Juergen" sort="Dethling, Juergen" uniqKey="Dethling J" first="Juergen" last="Dethling">Juergen Dethling</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Colman, Jessica" sort="Colman, Jessica" uniqKey="Colman J" first="Jessica" last="Colman">Jessica Colman</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Coward, Lorna" sort="Coward, Lorna" uniqKey="Coward L" first="Lorna" last="Coward">Lorna Coward</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Macgregor, Stuart" sort="Macgregor, Stuart" uniqKey="Macgregor S" first="Stuart" last="Macgregor">Stuart Macgregor</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">02-0494524</idno><date when="2002">2002</date><idno type="stanalyst">PASCAL 02-0494524 INIST</idno><idno type="RBID">Pascal:02-0494524</idno><idno type="wicri:Area/PascalFrancis/Corpus">005615</idno><idno type="wicri:Area/PascalFrancis/Curation">000B24</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">005462</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">005462</idno><idno type="wicri:doubleKey">0140-6736:2002:Punt C:edrecolomab:alone:or</idno><idno type="wicri:Area/Main/Merge">00C583</idno><idno type="wicri:Area/Main/Curation">00B758</idno><idno type="wicri:Area/Main/Exploration">00B758</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study</title><author><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J. A." last="Punt">Cornelis J. A. Punt</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medical Oncology, University Medical Center St Radboud, PO Box 9101</s1><s2>6500 HB Nijmegen</s2><s3>NLD</s3><sZ>1 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>6500 HB Nijmegen</wicri:noRegion></affiliation></author><author><name sortKey="Nagy, Attila" sort="Nagy, Attila" uniqKey="Nagy A" first="Attila" last="Nagy">Attila Nagy</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Csoinoky Hospital</s1><s2>Veszprém</s2><s3>HUN</s3><sZ>2 aut.</sZ></inist:fA14><country>Hongrie</country><wicri:noRegion>Csoinoky Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Douillard, Jean Yves" sort="Douillard, Jean Yves" uniqKey="Douillard J" first="Jean-Yves" last="Douillard">Jean-Yves Douillard</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre Rene Gauducheau</s1><s2>Nantes</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Figer, Arie" sort="Figer, Arie" uniqKey="Figer A" first="Arie" last="Figer">Arie Figer</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Ichilov Hospital</s1><s2>Tel Aviv</s2><s3>ISR</s3><sZ>4 aut.</sZ></inist:fA14><country>Israël</country><wicri:noRegion>Ichilov Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Skovsgaard, Torben" sort="Skovsgaard, Torben" uniqKey="Skovsgaard T" first="Torben" last="Skovsgaard">Torben Skovsgaard</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Heriev Hospital</s1><s2>Heriev</s2><s3>DNK</s3><sZ>5 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Heriev Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Monson, John" sort="Monson, John" uniqKey="Monson J" first="John" last="Monson">John Monson</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Hull</s1><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>University of Hull</wicri:noRegion></affiliation></author><author><name sortKey="Barone, Carlo" sort="Barone, Carlo" uniqKey="Barone C" first="Carlo" last="Barone">Carlo Barone</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Università Cattolica</s1><s2>Rome</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Fountzilas, George" sort="Fountzilas, George" uniqKey="Fountzilas G" first="George" last="Fountzilas">George Fountzilas</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Aristotle University of Thessalonlkl</s1><s3>GRC</s3><sZ>8 aut.</sZ></inist:fA14><country>Grèce</country><wicri:noRegion>Aristotle University of Thessalonlkl</wicri:noRegion></affiliation></author><author><name sortKey="Riess, Hanno" sort="Riess, Hanno" uniqKey="Riess H" first="Hanno" last="Riess">Hanno Riess</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Virchow Hospital</s1><s2>Berlin</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Moylan, Eugene" sort="Moylan, Eugene" uniqKey="Moylan E" first="Eugene" last="Moylan">Eugene Moylan</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Liverpool Hospital</s1><s2>New South Wales, Australia</s2><s3>AUS</s3><sZ>10 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Liverpool Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Jones, Delyth" sort="Jones, Delyth" uniqKey="Jones D" first="Delyth" last="Jones">Delyth Jones</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Dethling, Juergen" sort="Dethling, Juergen" uniqKey="Dethling J" first="Juergen" last="Dethling">Juergen Dethling</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Colman, Jessica" sort="Colman, Jessica" uniqKey="Colman J" first="Jessica" last="Colman">Jessica Colman</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Coward, Lorna" sort="Coward, Lorna" uniqKey="Coward L" first="Lorna" last="Coward">Lorna Coward</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author><author><name sortKey="Macgregor, Stuart" sort="Macgregor, Stuart" uniqKey="Macgregor S" first="Stuart" last="Macgregor">Stuart Macgregor</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>GlaxoWellcome (now GlaxoSmithKline) Research and Development</s1><s3>GBR</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>GlaxoWellcome (now GlaxoSmithKline) Research and Development</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Lancet : (British edition)</title><title level="j" type="abbreviated">Lancet : (Br. ed.)</title><idno type="ISSN">0140-6736</idno><imprint><date when="2002">2002</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Lancet : (British edition)</title><title level="j" type="abbreviated">Lancet : (Br. ed.)</title><idno type="ISSN">0140-6736</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Application method</term><term>Chemotherapy</term><term>Colon</term><term>Combined treatment</term><term>Comparative study</term><term>Edrecolomab</term><term>Fluoropyrimidine derivatives</term><term>Fluorouracil</term><term>Human</term><term>Malignant tumor</term><term>Pyrimidine derivatives</term><term>Randomization</term><term>Severity score</term><term>Stage classification</term><term>Treatment</term><term>Treatment efficiency</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Tumeur maligne</term><term>Côlon</term><term>Classification par stade</term><term>Indice gravité</term><term>Traitement</term><term>Chimiothérapie</term><term>Fluorouracil</term><term>Traitement associé</term><term>Edrécolomab</term><term>Etude comparative</term><term>Efficacité traitement</term><term>Randomisation</term><term>Modalité traitement</term><term>Anticancéreux</term><term>Homme</term><term>Fluoropyrimidine dérivé</term><term>Pyrimidine dérivé</term><term>Acide folinique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Edrecolomab is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary data suggested that it might be of use in the adjuvant treatment of patients with resected stage III colon cancer. We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients. Methods: After surgery, 2761 patients were randomly assigned edrecolomab plus fluorouracil-folinic acid (combination therapy [n=912]); fluorouracil-folinic acid alone (chemotherapy [n=927]); or edrecolomab alone (edrecolomab monotherapy [n=922]). Patients were assessed for survival and disease recurrence after surgery. The primary endpoint tested the hypothesis that combination therapy improved overall survival relative to chemotherapy. The key secondary endpoint was to test whether edrecolomab monotherapy was non-inferior to chemotherapy in terms of disease-free survival. Analysis was by intention to treat. Findings: Median follow-up time was 26 months (IQR 20-36). 3-year overall survival on combination therapy was no different from that on chemotherapy (74.7% vs 76.1%, hazard ratio 0-94 [95% Cl 0.76-1.15], p=0.53). Disease-free survival was significantly lower on edrecolomab monotherapy than on chemotherapy (53.0% vs 65-5%, 0.62 [0.53-0.73], p<0.0001). Hypersensitivity reactions occurred in 452 (25%) patients receiving edrecolomab, causing treatment discontinuation in 71 (4%). The addition of edrecolomab to chemotherapy did not increase neutropenia, diarrhoea, or mucositis. Interpretation: The addition of edrecolomab to fluorouracil and folinic acid in the adjuvant treatment of resected stage III colon cancer does not improve overall or disease-free survival, and edrecolomab monotherapy is associated with significantly shorter overall and disease-free survival than fluorouracil and folinic acid and is therefore an inferior treatment option. Edrecolomab is well tolerated and its addition to fluorouracil and folinic acid does not increase the toxicity of chemotherapy.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Danemark</li><li>France</li><li>Grèce</li><li>Hongrie</li><li>Israël</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Berlin</li><li>Latium</li><li>Pays de la Loire</li></region><settlement><li>Berlin</li><li>Nantes</li><li>Rome</li></settlement></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J. A." last="Punt">Cornelis J. A. Punt</name></noRegion></country><country name="Hongrie"><noRegion><name sortKey="Nagy, Attila" sort="Nagy, Attila" uniqKey="Nagy A" first="Attila" last="Nagy">Attila Nagy</name></noRegion></country><country name="France"><region name="Pays de la Loire"><name sortKey="Douillard, Jean Yves" sort="Douillard, Jean Yves" uniqKey="Douillard J" first="Jean-Yves" last="Douillard">Jean-Yves Douillard</name></region></country><country name="Israël"><noRegion><name sortKey="Figer, Arie" sort="Figer, Arie" uniqKey="Figer A" first="Arie" last="Figer">Arie Figer</name></noRegion></country><country name="Danemark"><noRegion><name sortKey="Skovsgaard, Torben" sort="Skovsgaard, Torben" uniqKey="Skovsgaard T" first="Torben" last="Skovsgaard">Torben Skovsgaard</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Monson, John" sort="Monson, John" uniqKey="Monson J" first="John" last="Monson">John Monson</name></noRegion><name sortKey="Colman, Jessica" sort="Colman, Jessica" uniqKey="Colman J" first="Jessica" last="Colman">Jessica Colman</name><name sortKey="Coward, Lorna" sort="Coward, Lorna" uniqKey="Coward L" first="Lorna" last="Coward">Lorna Coward</name><name sortKey="Dethling, Juergen" sort="Dethling, Juergen" uniqKey="Dethling J" first="Juergen" last="Dethling">Juergen Dethling</name><name sortKey="Jones, Delyth" sort="Jones, Delyth" uniqKey="Jones D" first="Delyth" last="Jones">Delyth Jones</name><name sortKey="Macgregor, Stuart" sort="Macgregor, Stuart" uniqKey="Macgregor S" first="Stuart" last="Macgregor">Stuart Macgregor</name></country><country name="Italie"><region name="Latium"><name sortKey="Barone, Carlo" sort="Barone, Carlo" uniqKey="Barone C" first="Carlo" last="Barone">Carlo Barone</name></region></country><country name="Grèce"><noRegion><name sortKey="Fountzilas, George" sort="Fountzilas, George" uniqKey="Fountzilas G" first="George" last="Fountzilas">George Fountzilas</name></noRegion></country><country name="Allemagne"><region name="Berlin"><name sortKey="Riess, Hanno" sort="Riess, Hanno" uniqKey="Riess H" first="Hanno" last="Riess">Hanno Riess</name></region></country><country name="Australie"><noRegion><name sortKey="Moylan, Eugene" sort="Moylan, Eugene" uniqKey="Moylan E" first="Eugene" last="Moylan">Eugene Moylan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B758 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00B758 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:02-0494524
|texte= Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
}}
| This area was generated with Dilib version V0.6.33. |  |